Contact

Daria Pašalić
Editor-in-Chief
Department of Medical Chemistry, Biochemistry and Clinical Chemistry
Zagreb University School of Medicine
Šalata ul 2.
10 000 Zagreb, Croatia
Phone +385 (1) 4590 205; +385 (1) 4566 940
E-mail: dariapasalic [at] gmail [dot] com

Useful links

P04-1

Đerek L, Unić A, Juriček J, Marijančević D, Romić Ž. PO4-1: Concetrations of human fetuin-A in hemodialysed patients. Biochemia Medica 2009;19(Suppl 1):S123.
Department for Laboratory Diagnostics, Dubrava University hospital, Zagreb, Croatia
Corresponding author:ldjerek [at] kbd [dot] hr
 
Abstract
 
Background: Metastatic calcifications are one of the complications in hemodialysed patients. Human fetuin-A (alpha2-Heremans-Schmid glycoprotein; AHSG) is a circulating inhibitor of calcification, and a potential predictor of their development. The aim of the study was to compare the concentrations of fetuin-A between hemodialysed patients and control group, and also between subgroups in hemodialysed patients depending on the duration of treatment.
Materials and methods: Our study included 92 participants; group of hemodialysed patients (N = 61 divided into subgroups depending on the duration of treatment (N1 = 34: treatment < 5 years; N2 = 27: treatment 5 years and more). Healthy participans were included in the control group (N = 31). Concentrations of fetuin-A were determined by ELISA. Statistical analysis was performed by univariant analysis of variance.
Results: Concentration of fetuin-A was 0.26 ± 0.069 g/L in the hemodialysed group as a whole; 0.25 ± 0.071 g/L in the N1 group; 0.26 ± 0.0046 g/L in the N2 group and 0.32 ± 0.057 g/L in the control group. Fetuin-A was significantly lower in hemodialysed group as a whole than in the control group (P = 0.001). Post-hoc analysis did not show significant difference between fetuin-A depending on the duration of the treatment.
Conclusion: Our study showed that fetuin-A was decreased in the hemodialysed group in comparison to the control group and that explains the greater pedisposition for the development of calcifications. Since there was no significant difference between the concentration of fetuin-A in subgroups depending on the duration of the treatment, the connection between fetuin-A, the presence of the calcifications, and classical markers of calcification development should be further investigated.